Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject).

Abstract: The present invention relates to semaglutide for use in weight management.

Abstract: The present invention is related to Mating Factor ? pro-peptide variants useful for the recombinant expression of polypeptides comprising a GLP-1 peptide in yeasts. The invention is also related to DNA sequences, vectors and host cells for use in expressing polypeptides in yeasts.

Abstract: The invention relates to a medical injection device having a polymeric housing or housing parts. The housing comprises a moulded outer housing element and a moulded elongated tubular inner housing element. The elongated tubular inner housing element is formed as one unitary element and carries a pointer and one or more projections in predetermined and correlated positions. The pointer points to indicia on a scale drum and the projections engage the scale drum. The outer housing element is moulded over the elongated tubular inner housing element in a 2K moulding to form one single housing component.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Abstract: An add-on device adapted to be releasably mounted on a drug delivery device, the add-on device comprising an outer assembly with an add-on dose setting member adapted to be coupled to the outer housing of a pen housing, as well as an inner sensor assembly engaging the pen dose setting member and being in rotational engagement with the add-on dose setting member during dose setting. The invention addresses the issue of providing a stable inner platform for the sensor means, which in accordance with the invention is realized by actuating a clutch between the pen housing and the pen dose setting member during dose sensing, this preventing to a high degree that the inner sensor assembly rotates relative to the drug delivery housing during actuation of the drug expelling means.

Abstract: A device for administering a fluid medicament by injection comprises a dosing portion (1) with a collapsible reservoir (10). The reservoir (10) has a maximum volume in an extended state and a minimum volume in a collapsed state. Prior to injection, the reservoir (10) is in the extended state and contains a liquid to be administered, and the reservoir (10) is biased towards the collapsed state. The device further comprises a needle (2), wherein a lumen (20) of the needle (2) is in fluid communication with the reservoir (10). The device further comprises a shield portion (3) with a plug (30). Prior to injection, the shield portion (3) is in a deployed position where the plug (30) blocks the lumen (20) of the needle (2). The shield portion (3) is adapted to move in response to an actuation force from the deployed position to a retracted position where the lumen (20) of the needle (2) is open, thereby causing the reservoir (10) to shift to the collapsed state to expel the liquid through the needle.

Abstract: 1. A drug delivery device for delivering a plurality of fixed doses of a medicament, wherein the drug delivery device comprises a needle magazine with a plurality of needle assemblies, a needle positioning mechanism, a drive mechanism for delivering a fixed dose of the plurality of fixed doses, in response to activation, an activation mechanism for activating the drive mechanism comprising a movable shield (110, 310), wherein the shield (110, 310) is adapted to activate the drive mechanism, in response moving the shield to the proximal position. The drug delivery device further comprises a drop lock mechanism comprising a non-blocking state and a blocking state.

Abstract: Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.

Abstract: A multi-use drug delivery device for extended use, wherein the multi-use drug delivery device comprising a multi-use main portion (310) and a single-use flow conducting device (360) adapted for conducting drug to the subcutaneous tissue of a subject, wherein the change from a connected configuration to an unconnected configuration of the main portion and the flow conducting device is through the intermediate configuration. The intermediate configuration comprises an equalizing channel defining an equalizing flow path (304) different from an unintended flow path (303).

Abstract: The present invention provides a drug injection device (100, 100?, 100?) comprising a first element (130) and a second element (102, 102?, 102?) configured to undergo movement relative to each other corresponding to an action performed on or by the drug injection device (100, 100?, 100?), wherein the first element (130) comprises serially disposed protrusions (133), and wherein the second element (102, 102?, 102?) comprises a second element base and a deflectable transducer (170, 170?, 170?). The deflectable transducer (170, 170?, 170?) defines a base portion attached to the second element base, and a deflectable portion (162) configured for sequentially cooperating with the plurality of protrusions (133), wherein a processor (165) is electrically connected with the deflectable transducer (170, 170?, 170?) to register activation signals.

Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Abstract: The invention relates to a medical injection device for dispensing substantially equally sized dose volumes of a liquid drug. The injection is driven by a torsion spring which is strained prior to each dose release by rotation of a connector element connecting the torsion spring to the rotational drive structure. The dose release is controlled by an axial movement of the rotational drive structure which can only be moved axially when the connector element has been rotated to a specific rotational position.

Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

Abstract: The invention provides antibody formulations and methods useful for prophylaxis or treatment of transthyretin-related amyloidosis.

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Abstract: Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Abstract: The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.